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Abstract: Cigarette smoking is the primary cause of lung cancer, cardiovascular diseases, 
reproductive disorders, and delayed wound healing all over the world. The goals of smoking 
cessation are both to reduce health risks and to improve quality of life. The development of novel 
and more effective medications for smoking cessation is crucial in the treatment of nicotine 
dependence. Currently, first-line smoking cessation therapies include nicotine replacement 
products and bupropion. The partial nicotinic receptor agonist, varenicline, has recently been 
approved by the US Food and Drug Administration (FDA) for smoking cessation. Clonidine and 
nortriptyline have demonstrated some efficacy, but side effects may limit their use to second-line 
treatment products. Other therapeutic drugs that are under development include rimonabant, 
mecamylamine, monoamine oxidase inhibitors, and dopamine D3 receptor antagonists. Nicotine 
vaccines are among newer products seeking approval from the FDA. Antidrug vaccines are 
irreversible, provide protection over years and need booster injections far beyond the critical 
phase of acute withdrawal symptoms. Interacting with the drug in the blood rather than with a 
receptor in the brain, the vaccines are free of side effects due to central interaction. For drugs 
like nicotine, which interacts with different types of receptors in many organs, this is a further 
advantage. Three anti-nicotine vaccines are today in an advanced stage of clinical evaluation. 
Results show that the efficiency of the vaccines is directly related to the antibody levels, a fact 
which will help to optimize the vaccine effect. The vaccines are expected to appear on the 
market between 2011 and 2012.
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Introduction
Tobacco smoking is the number one cause of premature death in developed 
  countries.1 It is responsible for approximately 400,000 premature deaths per year in 
the United States alone,2 and around 4.9 million deaths per year worldwide, or 8.8% 
of all deaths globally.3 Worldwide, more than 1 billion adults are regular tobacco 
smokers,4 and most of them use manufactured cigarettes.5 Smoking rates are high even 
among adolescents,6–9 which has led to smoking being labeled a pediatric disease or 
epidemic.10,11 Approximately half of all long-term smokers die prematurely as a result 
of smoking,12 and the life span of the continuing smoker will be reduced by 10 years 
on average.13 Smoking cessation provides major health benefits to men and women of 
all ages. For example, people who quit smoking by 50 years of age have half the risk 
of dying in the next 15 years compared with continuing smokers (around 10% versus 
20% at age 50, varying by sex and amount smoked).14Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
212
Escobar-Chávez et al
Although it is nicotine and its psychological effects that 
engender addiction,15,16 it is tobacco’s other components – 
‘tar’, volatile oxidant gases and carbon monoxide – that cause 
most of the damage to health.16–20
Nicotine replacement products are the first-line treatment 
for nicotine dependence approved by the US. Food and Drug 
Administration (FDA). Currently, there are many nicotine 
delivery devices available in the market – these include 
nicotine gum, transdermal patches, vapor inhalers, nasal 
spray, lozenges, and sublingual tablets.21 These treatments 
enhance cessation by delivering nicotine without exposure to 
the carcinogenic compounds found in cigarette smoke. The 
use of these nicotine replacement products has led to varying 
degrees of success in long-term smoking cessation,22 which 
has been reviewed extensively elsewhere.22,23 Newer products 
seeking approval from the FDA include nicotine vaccines. 
Immunologic approaches to treating tobacco dependence 
have three key advantages. First, immunization appears to be 
safe because of its low cross-reactivity with compounds other 
than nicotine. Second, immunization only requires a brief 
series of monthly injections to produce effects that can endure 
for months. The lack of major side effects and   relatively 
minimal dosing requirements could be associated with 
improved patient compliance. Third, its unique mechanism 
of action makes it well suited for combination with other 
pharmacotherapies.
This review focuses on recent advances that could lead 
to the development of therapeutic vaccines for smoking 
cessation.
Nicotine effects
Addiction is defined as a situation in which a drug unrea-
sonably controls behavior.24–27 Dependence-producing 
drugs often cause “tolerance”, physical dependence, and 
  pleasurable effects.1,28–35
Tobacco smokers inhale over 4,000 chemicals that 
have possible pharmacologic and toxicologic effects. 
Carbon   dioxide (CO2) and nitric oxide (NO) produce 
vascular dilatation, whereas nicotine produces primarily 
vasoconstriction.35,36 Nicotine is the primary component 
of tobacco that is responsible for maintaining smoking 
addiction.18,19   Animal models demonstrate nicotine’s addictive 
potential,37,38 and many studies have also shown nicotine’s 
addiction in humans.39
There is evidence that nicotine from smoking can improve 
some types of cognitive performance and vigilance.   Smokers 
often claim that smoking can both relieve stress and offset 
boredom or drowsiness. This may have its origin in the 
biphasic dose-related effects of nicotine, with low doses 
resulting in a stimulant effect, and higher doses resulting in 
a depressant effect.35 Moreover, nicotine can have short-term 
unpleasant side effects including dizziness, nicotine-induced 
nystagmus and nausea. These unpleasant effects appear 
more common in nonsmokers or light smokers than heavy   
smokers.36
Nicotine is a weak base containing a pyridine and 
a   pyrrolidine ring; each one possesses a tertiary amine 
 ( Figure 1). The pKa of the pyridine nitrogen is 3.04, whereas 
the pKa of the pyrrolidine nitrogen is 7.84 at physiologic 
temperature and ionic strength. With these characteristics, 
approximately 23% of nicotine is nonionized at physiologic 
pH and thus able to rapidly cross biological membranes.40–42 
Smoke from tobaccos used in pipes and cigars is more 
alkaline (pH = 6.5 or more), and as a result, nicotine is 
mostly unionized and well absorbed from the mouth.43 The 
plasma half-life (t1/2) of nicotine is approximately 2 hours. 
In the brain, the distributional t1/2 of nicotine is 10 minutes. 
Distributional t1/2 describes the time that it takes a nicotine 
dose to fall 50% from its peak level in the brain as the nicotine 
is distributed to other body compartments with a high affinity 
for nicotine (for example, the liver, spleen, kidney, lung).42,44 
Nicotine is absorbed from smoke into the circulation 
relatively quickly because of the large alveolar surface 
and large blood perfusion of the pulmonary circulation. 
During smoking, high levels of nicotine reach the brain in 
10–20 seconds after a puff, faster than with intravenous 
administration.42–44 Nicotine is extensively metabolized in 
the liver to six primary metabolites (nicotine glucuronide, 
nicotine N-oxide, nornicotine, nicotine isomethonium ion, 
cotinine, 2-hydroxynicotine). The predominant pathway 
during first-pass metabolism yields cotinine (in humans 
70%–80% of nicotine is metabolized to cotinine), which may 
N
N
CH3
Figure  1  Chemical  structure  of  nicotine  (with  permission  Bentham  Science 
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have some relevance in the diverse neurobiological effects 
of smoking as a ligand of nicotinic acetylcholine receptors 
(nAChRs).40,41 Unmetabolized nicotine excretion via the 
urine only accounts for about 5% of total elimination. The 
rate of nicotine metabolism is influenced by many factors, 
such as age, gender, food consumption, race, hepatic or renal 
diseases, pregnancy, and tobacco ingredients.17–20
Nicotine has a wide variety of effects on the central ner-
vous system (CNS) which impact behavioral function.20,45–49 
After nicotine enters the body, it binds to nAChRs of the CNS, 
specifically those in the brain, and initiates drug addiction. 
Once nicotine activates the nAChRs in the CNS, dopamine 
is released in the nucleus accumbens, a region important for 
the rewarding properties of the drug.16,41,50 Nicotine alters 
the function of several CNS neurotransmitters, including 
dopamine (DA), noradrenaline (NA), 5-hydroxytryptamine 
(5-HT), glutamate, gamma amino butyric acid (GABA) 
and endogenous opioid peptides (EOPs).51 In the brain, 
  nicotine acts via nAChRs, which are distinct members of 
the neurotransmitter-gated ion channel superfamily and 
have   crucial neuromodulatory roles in the CNS.52,53 The     
endogenous neurotransmitter at nAChRs is ACh.53,54,61,62   
Stimulation by nicotine of presynaptic nAChRs on these 
neurons increases neurotransmitter release and metabolism. 
Unlike most agonists, which downregulate the number of 
receptors with chronic exposure, the chronic administration 
of nicotine leads to desensitization and inactivation of 
nAChRs, and to a ‘paradoxical’ upregulation of nAChRs 
sites. After overnight abstinence, these nAChRs are likely to 
desensitize and are believed to be fully responsive to nicotine 
as an exogenous agonist.55,56
Chronic nicotine administration is thought to cause 
postreceptor changes such as changes in gene expression, 
and in protein synthesis and degradation in CNS neurons 
(such as the mesolimbic DA system), which lead to the 
complex processes of nicotine dependence and withdrawal.52 
In addition to nicotine, tobacco contains approximately 
2500 chemical compounds, while tobacco smoke consists 
of over 4000 chemical constituents, some of which have 
psychopharmacologic effects, and thus contribute to the 
nicotine dependence state in humans. Several compounds of 
smoke are generated by various mechanisms (combustion, 
pyrolysis, distillation) during the burning of tobacco.57,58 
Tobacco smoke has two phases, the gaseous phase and the 
particulate phase. The gaseous phase contains nitrogen 
oxide, carbon monoxide, carbon dioxide, ammonia, nitrites, 
alcohols, ketones (acetone, butanone), volatile sulfur-
containing compounds (hydrogen sulfide), hydrocarbons, 
aldehydes (formaldehyde and acetaldehyde), free radicals 
and other oxidants (hydrogen peroxide, superoxide anion and 
peroxynitrite). According to recent results, hydrogen peroxide 
probably has a role in airway tumorigenesis. The particulate 
phase contains alkaloids, water, and tar. Nicotine is the most 
abundant alkaloid in tobacco (accounting for 95% of the total 
alkaloid content).59
Smoking cessation therapies
Smoking cessation reduces premature deaths and improves 
prognosis and quality of life, so extensive, randomized, 
  double-blind, placebo-controlled clinical trials have estab-
lished the efficacy and safety of nicotine replacement 
therapies and bupropion and varenicline in the treatment 
of nicotine dependence. Of these, varenicline is the most 
effective for smoking cessation, followed by bupropion and 
nicotine replacement therapies.60
Evidence-based recommendations made by a private 
panel of experts (which can be found in “Treating Tobacco 
Use and Dependence: 2008 Update”),61 include seven 
  first-line therapies that have been approved by the US Food 
and Drug Administration (FDA) as smoking-cessation 
aids: nicotine replacement therapy, available in the form 
of a transdermal patch; a nasal spray; an oral inhaler; gum; 
a lozenge; bupropion sustained release, available as an oral 
tablet; and varenicline, available as an oral tablet. The guide-
line panel recommends clonidine and nortriptyline, which 
are not approved for this indication and are associated with 
an increased adverse-event potential, as second-line agents 
for smoking cessation. Clinical selection between first-line 
agents is considered a function of practical factors such as 
patient preference, time, and cost. Use of second-line agents 
may be considered on a case-by-case basis when first-line 
monotherapy or combination therapy is unsuccessful or 
contraindicated.61 Tables 1 and 2 summarize the nicotine and 
non-nicotine replacement therapies for smoking cessation.
Immunological methods
Immunization is a form of preventive medicine. Its aim is to 
protect individuals and communities from infectious   diseases. 
Immunization operates like an early warning system. It pre-
pares the body to fight against infection or immunogens. 
Immunization operates on the premise that once you have 
had a disease, you are unlikely to contract it again.114
Through injections, oral drops or scratches on the skin, 
the body is exposed to weakened or dead disease-producing 
microorganisms or to the toxins they produce. This will cause 
the individual to develop the same antibodies and antitoxins Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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that would have been developed if the person had actually 
contracted the disease, in order to fight the disease.115
Once the body has been exposed to an infection, the 
immune system will “recognize” a recurrence, and pro-
duce antibodies or antitoxins to destroy the infection or the 
immunogen. The body has to be exposed to infection once 
for the immune system to recognize it. This is done through 
immunization.116
Active versus passive immunization
Immunization against nicotine can be achieved by two 
methods. Active immunization (hereafter referred to 
as vaccination) involves repeated administration of an 
immunogen to the subjects being studied in order to stimulate 
the immune system to produce nicotine-specific antibodies. 
Passive immunization involves the production of antibodies 
in some other species (eg, rabbits) or in vitro, which are 
then purified and administered to the subjects being studied. 
Each method has advantages and disadvantages. Vaccination 
requires relatively few administrations (eg, one injection per 
month for 3 to 4 months) to produce a high serum level of 
antibody that persists for several months. It is also relatively 
inexpensive. The primary disadvantages of vaccination 
are the delay to achieving required antibody levels and the 
inability to control those levels. Passive immunization also 
offers several advantages, including the ability to: i) Achieve 
the required serum level of antibody virtually immediately, 
compared with the 1 to 2 months needed for vaccination; 
ii) control the antibody dose to study dose response 
relationships; and iii) examine the effects of high antibody 
doses that cannot be achieved with vaccination alone. The 
primary disadvantages of passive immunization are that 
Table 1 Nicotine replacement therapies and their combinations
Formulation Population Comments Refs.
Nicotine nasal spray ∼36% nonwhite smokers  
(Hispanic)
The proportion of patients who achieved smoking cessation  
was significantly greater with nicotine nasal spray compared  
with the nicotine transdermal patch. May cause nose and eye  
irritation or cough. Higher potential for addiction compared  
with other nicotine replacement therapies.
62–65
Transdermal nicotine patches British, native Alaskans  
and American indians
No significant findings favoring the use of nicotine  
transdermal patches were noted between the intervention  
and control groups.  
Emotional symptomatology appeared in patients: affective 
blunting; anhedonia with tiredness and lack of energy; anxiety; 
hypersensitivity; and tension. Less potential for addiction compared 
with gum.
63,66,67
Nicotine lozenge American, British (UK) Similar results among smokers regardless of success or failure  
of previous pharmacologic therapy. May cause mouth soreness or 
dyspepsia.
68,69
Nicotine inhaler British, American Flexible dosing; mimics hand-to-mouth action of smoking;  
few side effects. Frequent dosing necessary. May cause mouth  
and throat irritation. it is contraindicated for pregnancy  
category D, cardiovascular precautions.
63,70
Nicotine gum British, American Quit rates were higher in specialized cessation clinics than in  
primary care settings; higher potential for addiction than the patch. 
Avoid in patients with dental problems or  
temporomandibular joint syndrome.  
Cardiovascular precautions.
63,71,72
Transdermal nicotine patch  
and nicotine gum
Belgian Combination more effective than either agent alone. 73
Transdermal nicotine patch  
and nicotine spray
icelander Combination more effective than either agent alone. 74
Transdermal nicotine patch  
and nicotine inhaler
French Combination more effective than either agent alone. 75
Group-based cognitive– 
behavioral therapy and  
transdermal nicotine patches
African-American, American The results show that 7-day point prevalence abstinence  
was significantly greater in the group-based cognitive– 
behavioral therapy than the group general health education  
at the end of counseling (51% versus 27%), at 3 months  
(34% versus 20%), and at 6 months (31% versus 14%).  
Long-term quit rates could be improved by education programs.
76,77Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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Table 2 Non-nicotine replacement therapies and their combinations
Formulation Population Comments Refs.
varenicline Asian Helps patients achieve smoking cessation by reducing  
cravings/withdrawal symptoms and smoking satisfaction.  
The most commonly reported adverse effects for varenicline,  
bupropion sustained release, and placebo in the pooled  
analysis were nausea (28.8%, 9.9%, and 9.1%, respectively),  
insomnia (14.2%, 21.5%, and 12.6%), and headache (14.2%,  
11.1%, and 12.4%). Particular attention with patients with  
comorbid conditions such as those with psychiatric disorders  
and cardiovascular disease. There is no consistent evidence  
that varenicline reduces weight gain compared with placebo.
78–85
Bupropion sustained release African-American Smokers abstain at a significantly greater rate (P , 0.05)  
when using bupropion sustained release versus placebo.
86
Bupropion sustained release American The efficacy of bupropion has been confirmed in several  
large studies. its most common side effects (occurrence  
.1:100) are dry mouth, headache, nausea and insomnia  
and its most rare side effects (occurrence .1:10,000  
and ,1:1000) are seizure, severe hypersensitivity reaction. 
Moreover, bupropion has been reported more effective  
than the nicotine patch. Bupropion advantage is that it  
reduces post-cessation weight gain (0.8 kg), compared  
with nicotine replacement therapies by 0.5 kg.
87–91
Nortriptyline American, Brazilian in controlled clinical trials nortriptyline alone has shown  
to be effective with odds ratios ranging from 1.2 to 5.5,  
for smoking cessation in four studies, with only one study  
lacking a statistically significant benefit. The smoking  
cessation rates achieved with nortriptyline appear to be  
comparable to those achieved with bupropion. Common  
side effects reported are dry mouth, light-headedness,  
shakiness, and blurred vision, although urinary retention,  
constipation, sexual difficulties, and risk of seizures.
92–96
Clonidine (can be taken orally  
or through a transdermal patch)
American, Chinese, French Placebo-controlled clinical trials indicate that clonidine is  
superior to placebo (2.4 and 2.0 ratios). This is comparable  
with the efficacy of nicotine replacement therapies and  
bupropion. It may be beneficial in female smokers.  
Significant side effects, such as dry mouth, dizziness and  
postural hypotension make its use less desirable. Patients  
with a history of depression or occlusive peripheral  
vascular disease should avoid using clonidine.
97–99
Endogenous Opioids (EOPs) 
– naltrexone
American There is conflicting evidence for the effectiveness of  
naltrexone monotherapy for smoking cessation.
100
Naltrexone and Transdermal  
nicotine patch
84.3% of white American Treatment with low-dose naltrexone does not significantly  
reduce weight gain or improve smoking cessation in highly  
weight-concerned smokers. Given that this population  
gained relatively little weight even on placebo, cognitive  
interventions to reduce weight concerns in combination  
with approved smoking cessation pharmacotherapy are  
preferable. Nevertheless, there may be other sub-populations  
of smokers at risk of substantial weight gain following  
smoking cessation for whom the weight suppressing  
effects of naltrexone might be of benefit.
101
Naltrexone and bupropion white American, American,  
non-obese adults, overweight  
and obese adults
Smoking cessation rates are similar to bupropion, but there  
was a significant trend for less weight gain with the  
combination than with placebo and monotherapy.
102,103
Naltrexone and bupropion both  
sustained release formulations,  
plus behavioral counseling
93.3% white American with  
overweight or obese adults
Combination decreased nicotine use, limited nicotine  
withdrawal symptoms, and no significant weight gain.  
The most common adverse events were nausea, insomnia,  
and constipation.
104
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it requires more frequent injections to maintain required 
antibody levels and is more expensive than vaccination.
vaccine formulation and administration
Nicotine is too small (molecular weight 167 kD) to elicit an 
immune response (ie, it is not immunogenic). Thus, regular 
tobacco users do not have antibodies against it. Nicotine is 
rendered immunogenic by conjugating (linking) the drug 
itself or a structurally related compound (a hapten) to an 
immunogenic carrier protein to form a complete immu-
nogen, referred to as a conjugate vaccine. Various types 
of carrier proteins have been employed, including keyhole 
limpet hemocyanin (KLH),114–116 a 19-residue peptide,117 
  recombinant cholera toxin B subunit,118 and recombinant 
pseudomonas exoprotein A.119 The latter two have the 
  advantage of having been used previously in   vaccines 
administered to humans. The conjugation of nicotine 
to a carrier protein has typically been accomplished using 
a linker, such as succinic acid. One vaccine in development   
uses virus-like particles formed from the bacteriophage Qb 
instead of a carrier protein.120,132 Most vaccines are prepared 
for administration by mixing the complete immunogen with 
an adjuvant (eg, Freund’s in animals, alum in humans), which 
enhances the immune response. The peptide-based vaccine 
mentioned above does not use additional adjuvant. After the 
initial injection of vaccine, periodic booster doses are needed 
to maintain satisfactory antibody levels, since exposure to 
nicotine by itself does not elicit an anamnestic (booster) 
response. Vaccination schedules in rats typically involve 2 
to 4 injections at 2 to 4 week intervals. No studies have been 
published directly comparing different schedules to suggest 
an optimal one. Vaccination schedules during early clinical 
trials in humans have involved 2 to 6 injections also at 2 to 
4 week intervals.
Specific vaccines and antibodies
The effects of nine different nicotine vaccines have been 
reported in rodents,114–118,120–121 three of which have been   
tested in Phase I and II clinical trials.120,125 The effects of   
passive immunization using various forms of   nicotine-  specific 
Table 2 (Continued)
Formulation Population Comments Refs.
Selective serotonin reuptake  
inhibitors (SSRis)  
– fluoxetine and paroxetine
British, American Significant short-term effect (6 months). None demonstrated  
any long-term benefit.  
An analysis of fluoxetine trials with negative results indicated  
some benefit in the subgroup of smokers who had a history  
of major depression.
105,106
Selective serotonin reuptake  
inhibitors (SSRis)  
Anxiolytics:  
– buspirone  
– diazepam  
– meprobamate  
– propanolol  
– metoprolol  
– oxprenolol  
– ondansetron
American, British Buspirone does not cause physical dependence. However,  
a placebo-controlled trial failed to support its efficacy in  
smoking cessation.  
Anxiolytics have been examined to aid smoking cessation,  
finding no or unclear effects on abstinence or withdrawal  
symptoms.
107,108
Mecamylamine American and Canadian Mecamylamine reduces cholinergic activity, so it was  
hypothesized that it may reduce urges to smoke by blocking  
the rewarding effect of nicotine, and be most effective  
when combined with nicotine replacement therapies.  
Mecamylamine, compared to placebo, increased the  
number of cigarettes smoked and plasma nicotine levels.  
Moreover, it increased smoking intensity and resulted in  
greater plasma nicotine levels in smokers with schizophrenia  
compared to controls.
109–111
Monoamine oxidase (MAO) 
inhibitors:  
– moclobemide  
– selegiline hydrochloride
American and Canadian in one long term trial, moclobemide was found to have a  
significant effect on smoking cessation at 6 months, but not  
at 1 year, compared with placebo.  
Selegiline hydrochloride was safe and well-tolerated by  
adult cigarette smokers, but did not improve smoking  
abstinence rates compared to placebo. A common adverse  
effect reported for selegiline hydrochloride was dry mouth.
112,113Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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antibody have also been examined in several   studies in 
rodents.113,114,117,126 Although the formulation varies between 
these vaccines and antibodies, their mechanism of action is 
the same and their pharmacokinetic and behavioral effects 
in animals and humans are generally similar.
Antibody characteristics
Three characteristics of vaccines that are relevant to   treating 
drug abuse include immunogenicity, and the affinity and 
specificity of the elicited antibodies. Immunogenicity refers 
to the serum concentration of antibody that is achieved. 
In order to be maximally effective, a vaccine must elicit 
and maintain a high serum concentration of antibody 
throughout the period of interest, because higher ratios of 
antibody to   nicotine result in greater binding of nicotine in 
serum.   Affinity refers to the strength with which the elicited 
antibodies bind the drug. Specificity refers to the extent to 
which the antibodies bind nicotine in preference to other 
compounds.
Greater specificity reduces competition from other 
compounds for binding capacity, improves safety, and reduces 
the likelihood of adverse side effects. Vaccine formulation 
can influence these three properties. For example, specificity 
is influenced by linker position. Linkers that are distant 
from prime sites of metabolism help to elicit antibodies 
that preferentially bind nicotine over its metabolites.58,117 In 
addition, immunogenicity appears to be influenced by the 
design of the hapten.120
All of the vaccines studied to date in animals have been 
sufficiently immunogenic to elicit significant concentrations of 
nicotine-specific antibody in serum (eg, 180–250 µg/mL).58,127 
That bind nicotine with high affinity (eg, Kd [affinity constant 
antigen-antibody] 37–50 nM).117,118 These antibodies also 
generally show high specificity for nicotine, as binding of 
other compounds is very low (cross-reactivity with other 
compounds such as nicotine metabolites, acetylcholine, or 
other neurotransmitters is typically less than 5%).58,59,116,118
Vaccines against nicotine
Vaccines against nicotine are at an advanced stage of clinical 
evaluation in many places, but are not yet approved for treat-
ment of individuals.
Nicotine itself is a very small molecule (Figure 1) and is 
not able to induce antibodies directed against it. But it can 
be chemically linked to a carrier protein, which renders the 
nicotine molecule visible to the immune system.
Immune complexes formed in the body have a   tendency 
to deposit and to lead to severe immune-complex induced 
diseases such as serum disease, Arthus reaction and 
  immune-complex related glomerulonephritis or Sanarelli–
Shwartzman phenomenon. Treatments leading to immune-
complex deposits are dangerous for the patient.
However, nicotine is a small molecule and allows only 
one antibody to bind at a time. Large pathologic immune 
complexes can therefore not be formed, as their construction 
requires more than one binding site.128
The antibodies elicited by a nicotine vaccine conjugate 
circulate in the blood stream and bind to the nicotine as it 
enters the body through the lungs. After the binding of the 
antibody to nicotine, the nicotine-antibody complex cannot 
cross the blood–brain barrier due to its size. There is no 
nicotine-induced cerebral stimulation and for the smoker 
the impression is comparable to smoking a cigarette without 
nicotine. The vicious circle between smoking and nicotine-
induced stimulation is broken. The antibodies don’t have any 
effect on withdrawal symptoms. The craving of the smoker 
for nicotine is not affected but smoking can’t satisfy the 
craving any more.
The interaction of antibodies with nicotine is a revers-
ible interaction and each antibody releases and binds 
nicotine many times, the way a juggler catches and releases 
  multiple sticks many times. This is one of the reasons that 
the observed binding capacity of the antibodies for nicotine 
is far in excess of what a simple stoichiometric calculation 
would let us expect. Pentel et al have observed a protective 
effect in a rat model under conditions where the daily 
nicotine dose given exceeded the calculated theoretical 
nicotine binding capacity of the antibodies in the animal by 
more than 33 times.119 In view of the reversible nature of 
the antibody binding to nicotine, some of the nicotine will 
reach the receptor. But there is a very significant delay and 
the dependence-inducing stimulation is based on an almost 
instantaneous stimulation after application.
The protective effect of the anti-nicotine vaccine in a 
mouse model129 has been evaluated under conditions of a 
continuous challenge with a very high nicotine dose, with 
the help of osmotic pumps which were surgically implanted 
under the skin. The pumps delivered 1.5 mg/kg/day of 
nicotine over a period of 4 weeks to each of the animals. 
This corresponds to the nicotine equivalent of four to five 
packages of cigarettes for a 70 kg man per day, assuming 
that 1 mg nicotine is absorbed by the body per cigarette. 
At the end of the 4 weeks the animals were challenged with 
a bolus of radioactively labeled nicotine, corresponding 
to two cigarettes, in order to check if the vaccine was still 
  effective. The mice were sacrificed 5 minutes later, the brain Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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was extracted and the nicotine concentration in blood and 
brain was measured separately.
In vaccinated animals the nicotine concentration was 
significantly higher than in control animals as the antibodies 
concentrated the drug in the blood. The nicotine concentration 
in the brain of the vaccinated animals 5 minutes after nicotine 
challenge was only a fraction of the concentration in the con-
trols, because the nicotine was retained outside the brain.
Vaccines against nicotine under 
evaluation in clinical trials
Three companies are at an advanced stage of clinical trials 
and have reported some results so far (Table 3).
All anti-nicotine vaccines in development, with the 
exception of the vaccine developed by Sanderson et al,117 are 
classical vaccine constructs made up of a an adjuvant and a 
nicotine carrier protein conjugate, and are administered by 
injection. Cytos AG uses a proprietary virus-like particle 
as carrier protein, whereas NabiInc and Celtic Pharma 
use bacterial toxin components. The vaccine developed 
by Sanderson et al at the University of Nebraska uses a 
modified form of the complement compound C5a as its 
carrier compound. The adjuvants used in the clinical trials 
are classical adjuvants such as alum hydroxide or phosphate. 
The information in the public domain as far as the adjuvants 
are concerned is not complete and the companies may 
evaluate proprietary adjuvant formulations in their trials. The 
mode of administration of the vaccines in the clinical trials 
reports has been limited to injection. The three companies 
are regularly updating ongoing studies on their websites and 
in professional congresses, as well as through publications 
in peer-reviewed journals (www.cytos.ch, www.nabi.com, 
www.celticpharma.com).130 Table 4 shows the inclusion and 
exclusion criteria for the clinical trials of these companies.
Results of Phase I studies by NabiInc and Cytos, reported 
as conference abstracts, suggest that these vaccines are safe, 
well tolerated, and immunogenic.131 Cytos has successfully 
completed a Phase I study with 40 healthy nonsmoking 
  volunteers. So far, results of a Phase I trial by Cytos have 
shown no unexpected toxicities and Phase II trials have 
started in Switzerland (Cytos).132
Preliminary results of the Phase II study indicate that 
the strength of the immunologic response to the vaccine 
varies among individuals. Among individuals with antibody 
responses in the highest tertile, continuous abstinence rates 
were significantly higher and cigarette consumption was 
significantly lower than among subjects who received a pla-
cebo vaccine. Abstinence rates and cigarette consumption 
among subjects with antibody responses in the middle or 
lower tertiles were not significantly different from the   placebo 
group.133
Cytos AG, Schlieren Switzerland
Phase i study of the anti-nicotine vaccine NiB002
Cytos’s nicotine vaccine program is today partnered with 
Novartis AG. Cytos started in April 2003 with the clinical 
development of the nicotine vaccine candidate NIC002 and 
performed a double-blind placebo-controlled Phase I study 
evaluating safety, immunogenicity and tolerability of the 
vaccine. The study evaluated four groups of 10 healthy non-
smoking volunteers with different doses and preparations 
of the vaccine. All patients responded with high levels of 
nicotine-specific antibodies and a long lasting immune 
response. The antibody level showed a decline over time, as 
expected. Adverse effects, reported in up to half of the par-
ticipants, mainly involved elevated body temperature, feeling 
cold and muscle ache (the injections were done intramus-
cularly). Those symptoms mostly disappeared within 1 day 
and Cytos AG concluded that the vaccine was sufficiently 
immunogenic and safe.
Phase ii study of vaccine NiB002
The randomized, placebo-controlled double-blind study 
included 341 smokers. Two-thirds of the cohort received 
the active vaccine and one-third a placebo vaccine. 
All participants receiving the active vaccine and none of 
the control group developed nicotine specific antibodies. 
Five injections of 100 µg of vaccine conjugate were given 
at monthly intervals and the participants were counseled at 
each visit for the first 3 months. The efficacy criteria were 
defined as strict abstinence from week 8 to 24 and from 
week 8 to 52 after beginning treatment. Self-reporting as 
well as biochemical markers were used for the evaluation 
of abstinence of smoking. The vaccine was well tolerated 
Table 3 Companies and countries involved in the design and 
development of vaccines for smoking cessation
Country
Main companies
Cytos AGN Switzerland
Nabi, inc United States
Celtic Pharma United Kingdom
Other companies 
Chilka Ltd
 
British virgin islands
Scripps 
Pharmaceutica AB
San Diego, USA 
Stockholm, Sweden
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but up to 70% of the participants reported local reactions 
and flu-like symptoms, which disappeared within 24 hours. 
No side effects were reported during the follow-up period 
between month 6 and 12. Six-month results were published 
in May 2005 and 12-month results in November of the 
same year. There was a subgroup of 239 patients who 
did not use nicotine replacement products and for whom 
complete antibody measurements were available at month 6. 
According to the antibody levels those smokers were divided 
into three equal groups corresponding to low-, medium- and 
high-responder groups. The continuous abstinence in the high 
responder group after 6 and 12 months was 57% (P = 0.004 
as compared to the placebo group) and 42% respectively. The 
equivalent result in the medium responder group was 32% 
and 21% respectively, and in the low responder group, 32% 
and 26%, respectively. The continuous abstinence rate in the 
placebo group was quite high at 31% and 21%. A subsequent 
study with healthy volunteers evaluated a dose of 300 mg of 
conjugate instead of 100 µg per injection. Cytos claims the 
higher dose induced a mean antibody level four times higher 
than in the initial Phase II study where 100 µg were injected. 
The company also reported on additional study protocols 
where 100 µg were injected five times weekly or five times 
bi-weekly or five times monthly. A graph with data from this 
study shows specific antibody titers after five weeks with the 
weekly immunization regime were about four times higher 
than the antibody levels of the monthly immunization regime 
after four injections. In the same presentation, the bi-weekly 
immunization schedule shows a slower increase in antibody 
levels then the weekly injections. Graphs of the results can 
be viewed on Cytos’ website (www.cytos.ch).
Cytos has also reported on the testing of a new formulation 
of NIC002 with the aim of achieving better tolerability of 
the vaccine. The company claims the new formulation has 
reduced the incidence of fever from nearly 40% to almost 
zero and has reduced the incidence of flu-like symptoms from 
up to 70% to about 10%.132–139
Celtic pharma holdings LP
The initial vaccine development of Celtic Pharma’s vaccine 
goes back to Immulogic Pharmaceutical Company’s 
development program for a nicotine vaccine in 1997. 
  Cantab Pharmaceuticals PLC acquired Immulogic’s nico-
tine and cocaine vaccine program in 1999 and the company 
merged in 2001 with Xenova Group PLC. Celtic Pharma 
Holdings LP took over Xenova in 2005 and announced 
in April 2007 that they had obtained Investigational New 
Drug (IND) approval for their nicotine vaccine candidate 
TA-NIC.
Xenova Group PLC in the United Kingdom has already 
completed two Phase I/II studies involving 120 patients with 
Celtic Pharma’s vaccine candidate. Those prior trials showed 
efficacy and only minor side effects.
The new Phase IIB study, which Celtic started in the 
United States, is a placebo-controlled double-blind study and 
will also evaluate the efficacy of the vaccine when current 
standard support treatments are given. All treatment arms 
receive professional counseling. The study is a multicenter 
trial that includes different doses of the vaccine and enrolls 
up to 200 patients in each of the three treatment arms. The 
primary endpoint of the study is the abstinence rate 6 month 
after the initial vaccination.137,139,140
Table 4 inclusion and exclusion criteria for the clinical trials of main companies involved in the development of smoking cessation 
vaccine
Company Inclusion criteria Exclusion criteria
Cytos AGN Participants between 18 and 70 years, to have been  
smoking at least 10 but no more than 40 cigarettes/ 
day for more than 3 years, and willing to quit smoking.  
women of childbearing age had to agree to use an  
effective form of contraception during treatment and  
up to 12 months after the last dose of the vaccine.
Cardiovascular, renal, pulmonary, endocrine, or neurological 
disorders, ulcers, skin disorders, autoimmune diseases or severe 
allergies; behavior likely to promote Hiv acquisition; an active 
liver infectious disease; a current diagnosis or a history of major 
depressive episodes, of panic attacks, psychosis, bipolar or 
eating disorders; use of other smoking-cessation treatments, like 
bupropion or nicotine replacement therapy within 6 months before 
study enrollment or at the time of screening; pregnancy or lactation; 
abuse of alcohol or other recreational drugs; use of a psychoactive 
drug (excluding sleeping pills) within one month before enrollment; 
and regular use of any non-cigarette tobacco product.
Nabi, inc Participants between 20 and 65 years, willing to  
quit smoking.
Cardiovascular, renal, pulmonary, endocrine, or neurological 
disorders, not using other smoking cessation therapies for at least 
six months before the study.
Celtic Pharma Participants between 18 and 70 years, willing to  
quit smoking.
Cardiovascular, renal, pulmonary, hepatic, endocrine, or 
neurological disorders, ulcers, and autoimmune diseasesDrug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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Completed enrollment for the Phase IIB clinical study 
in the US was announced by Celtic in October 2007 
after recruiting over 520 patients in 10 weeks and stated 
that more than half the patients had already received the 
seven doses of vaccine, which the study protocol calls for. 
The dropout rate was less than 10% and Celtic expected 
the results of the study in the second quarter of 2008. 
Like the other two companies (Cytos Biotechnology and 
Nabi Pharmaceuticals), Celtic has completed Phase II 
studies. Filing for FDA approval had been expected to 
follow in 2009, although Phase III study results have not 
yet been published for (TA-NIC vaccine). Celtic Pharma 
has also reported clinical trial results of an anti-cocaine 
vaccine.138–140 Celtic expects to obtain FDA approval in 
2010 for their cocaine vaccine.
Nabi inc
Nabi announced the successful completion of the Phase IIB 
trial of their anti-nicotine vaccine in November 2007. Earlier 
publications reporting on the development of the vaccine 
reported on a conjugate with Pseudomonas aeruginosa exo-
protein A as a carrier protein and 3’-aminomethylnicotine as 
a hapten. The trial was a double-blind, placebo-controlled, 
dose-ranging study in preparation for the Phase III study. 
The trial’s primary endpoint is the rate of carbon monoxide 
(CO)-confirmed, continuous abstinence from smoking during 
weeks 19–26 after first application of the vaccine. The 
12-month continuous abstinence with the 400 µg schedule 
was 16% versus 6% for the placebo group, and 14% versus 
6% for the placebo group with the 200 µg immunization 
schedule. There was a strong correlation between antibody 
level and continuous abstinence: the top 30% antibody 
responders showed a continuous abstinence rate of almost 
three times the rate of the placebo group after 12 months. The 
vaccine was well tolerated and the vaccine group showed at 
each stage of the study a comparable adverse event profile 
to the placebo group.
Nabi reported results of an improved immunization 
schedule in July 2008, which was based on the 400 µg dose 
and six applications of the vaccine. Based on this schedule 
80% of the subjects achieved the target antibody level at 
14 weeks, which compares to only 50% of subjects with the 
prior immunization schedule. Nabi announced the Phase III 
clinical trial would start before the end of 2008.131,141,142 
To date, Nabi has developed antibodies produced by 
a single injection, which last about 1 month. Currently, they 
are working at designing multiple sequences to be tested in 
order to extend the response for several months.145
Chilka Ltd and other competitors 
developing nicotine vaccines
Chilka Ltd is registered in the British Virgin Islands. The 
company intends to initiate a combined Phase I/II clinical 
trial in 2011. A peptide based nicotine vaccine linking 
nicotine to a modified form of the complement component 
C5a has been developed at the University of Nebraska 
and may also move to clinical evaluation.119 Nicotine 
vaccines are also being developed at Scripps123,143,144 in 
San Diego, CA. Pharmaceutica AB, a Swedish company 
based at the Karolinska Institute in Stockholm intends 
to start a clinical trial with its anti-nicotine vaccine in   
2011.146–148
Further developments to expect
At this stage, clinical trials are concerned with efficacy and 
safety, and other considerations such as ease of application 
and price are not the primary concern, but it seems reasonable 
to expect over the coming years to see a differentiation of 
the vaccine products for commercial use. Intramuscular 
  injections are painful, especially if used in vaccination 
protocols requiring as many as six injections. It seems 
  reasonable to expect that subcutaneous application of the 
  vaccine will replace intramuscular application in those 
  protocols. Nicotine enters the body through the mouth, 
the trachea and the lungs, which are lined with mucous 
surfaces containing high levels of IgA antibodies.
Lindblom et al147 have shown in a mouse model that   
intranasal immunization is able to elicit significant levels of 
antibodies and we would expect some of the future application 
schedules to use intranasal application forms of the vaccine.
None of the vaccine studies carried out so far has reported 
major side effects. Some of the studies report on minor side 
effects, limited in most cases to the site of injection and which 
are of short duration.
The incidence of reported minor site effects is getting 
lower as the studies proceed, which means that appropriate 
measures concerning the formulation and scheduling of the 
vaccine have been taken.
All vaccines under evaluation have been assessed as 
therapeutic vaccines and one may ask if a prophylactic nico-
tine vaccine could be envisioned. From the theoretical point 
of view, one would be inclined to answer in the affirmative, 
as the immune system is mature years before a person may 
consider lightening up his or her first cigarette.
But, on the other hand, it does create a dangerous prec-
edent if one replaces education with a vaccine. Where does 
this stop? Hasman et al149 have argued that an anti-nicotine Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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vaccine may interfere with therapeutic uses of nicotine 
later in life, a situation which could arise if the vaccinated 
person develops ulcerative colitis. The incidence of the 
disease in the USA is modest (35–100 per 100,000) and 
nicotine is neither the only nor the preferred form of treat-
ment. Furthermore, we would expect that nicotine will have 
a therapeutic efficacy, as it still arrives at the receptor.149 
Marketing launch dates for these nicotine vaccines have 
not yet been announced.150 Phase III trials and regulatory 
approval typically take a long time and we would expect the 
first nicotine vaccines to be commercialized between 2011   
and 2012.
Conclusion
Immunization against nicotine can significantly attenuate 
several behavioral effects of nicotine in animals that 
are   considered relevant to tobacco dependence in humans. 
These findings suggest that immunologic interventions could 
have use in the treatment of tobacco dependence. Initial 
clinical trials have demonstrated that nicotine vaccines are 
safe and produce substantial serum levels of nicotine-specific 
antibody in humans. Although preliminary data from these 
small trials suggest that vaccination may facilitate absti-
nence from tobacco use, more advanced trials are needed 
to validate this finding. Taken together, the research to date 
suggests that immunologic interventions could play an 
important role in future treatments for tobacco dependence. 
The primary role of such interventions will probably be in 
preventing relapse in smokers who are motivated to quit. 
By preventing a lapse by producing positive subjective and 
reinforcing effects, vaccination may prevent progression 
to full relapse. Another potential role for immunologic 
interventions is in facilitating reduction of tobacco use in 
people who are unwilling or unable to quit. It is generally 
accepted that the most effective approach to treating tobacco 
dependence is the concurrent use of medications and behav-
ioral therapy. Despite the significant therapeutic potential 
of immunologic interventions, they do not target the non-
pharmacological factors that maintain tobacco dependence 
and will probably be maximally effective when combined 
with behavioral interventions that motivate abstinence from   
tobacco use.
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